Dawes S, Joy McGreal S, Marwaha S, Prados J, Reheis A, Dumitrescu A, Waddington JL, Moran PM, O’Tuathaigh C. (2024) Overshadowing and Salience Attribution in Relation to Cannabis Use. Schizophrenia Research Cognition. In Press.

Maggi S, Hock RM, O’Neill M, Buckley MJ, Moran PM, Bast T, Sami M, Humphries MD (2024) Tracking subject’s strategies in behavioural choice experiments at trial resolution . eLife 13:e86491.

Granger KT, Sand M, Caswell S, Lizarraga L, Barnett JH, Moran PM. A new era for schizophrenia drug development–Lessons for the future. (2023) Drug Discovery Today. May 2:103603.

Moran PM, Granger KT, Treherne MJ, Barnett J (2023) Post-Covid-19 cognitive impairment: a new target for drug development ? Drug Discovery World April 20th

Treherne MJ, Barnett J, Moran PM (2022) The rise of digital biomarkers in neuroscience drug development. Drug Discovery World. Oct 10th.

Dawes C, Quinn D, Bickerdike A, O’Neill C, Granger KT, Pereira SC, Mah SL, Haselgrove M, Waddington JL, O’Tuathaigh C, Moran PM. (2022) Latent inhibition, aberrant salience, and schizotypy traits in cannabis users. Schizophrenia Research: Cognition;28:100235.

Dawes C, Bickerdike A, O'Neill C, Carneiro Pereira S, Waddington JL, Moran PM, O'Tuathaigh CM. Cannabis Use, Schizotypy and Kamin Blocking Performance(2021). Frontiers in psychiatry. 2021:2104.

Dawes C, Danielmeier C, Haselgrove M, Moran Paula M.(2021) High Schizotypy Predicts Emotion Recognition Independently of Negative Affect.  Frontiers in Psychiatry vol 12 pp 1580

Granger KT, Ferrar J, Caswell S, Haselgrove M, Moran PM, Attwood A, Barnett JH. Effects of 7.5% Carbon Dioxide and Nicotine Administration on Latent Inhibition. Frontiers in Psychiatry. 2021 Apr 16;12:582745.

O'Tuathaigh C, Dawes C, Bickerdike A, Duggan E, O'Neill C, Waddington, JL Moran PM (2020) Does cannabis use predict psychometric schizotypy via aberrant salience?,Schizophrenia Research, Volume 220, 194-200.

Mathur N, Dawes C, Moran PM. 2019. Olfactory threshold selectively predicts positive psychometric schizotypy. Schizophrenia Research. 209:80-87.

Bailey SJ, Neill JC, Moran PM. Pharmacology of cognition: a panacea for neuropsychiatric disease? 2017. British Journal of Pharmacology. 2017 174(19):3133-3135.

O'Tuathaigh CMP, Mathur N, O'Callaghan MJ, Lai M, Harvey R, Waddington JL, Pickard B, Watson D and Moran PM 2017. Specialised information processing deficits and distinct metabolomic profiles following TM-domain disruption of NRG1. Schizophrenia Bulletin. 43 (5) 1110-1115.

Oyegbami O, Collins H, Pardon MC, Ebling F, Heery DM and Moran PM, 2017. Abnormal clock gene expression and locomotor activity rhythms in two month old female APPSwe/PS1dE9 mice. Current Alzheimer Research. 

O'Tuathaigh CMP, Moran PM, Zhen XC and Waddington JL, 2017. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. British Journal of Pharmacology. 174(19):3173-3190.

Fulton J, Mazumder B, Whitchurch J, Monteiro C, Collins H, Chan C, Clemente M, Hernandez Quiles M, Stewart E, Amoaku W, Moran PM, Mongan N, Persson J, Ali S and Heery DM, 2017. Heterodimers of Photoreceptor-Specific Nuclear Receptor (NR2E3) and Peroxisome Proliferator-Activated Receptor (PPARγ) are Disrupted by Retinal Disease-Associated Mutations. Cell Death and Disease. 8, e2677

Granger K, Moran PM, Buckley M and Haselgrove M, 2016. Enhanced latent inhibition in high schizotypy individuals. Personality and Individual Differences. 91, 31-39.

Moran PM, Stokes J, Marr J, Bock G, Desbonnet L, Waddington JL and O'Tuathaigh CMP (2016) Gene-environment interactions in schizophrenia: evidence from genetic mouse models Neural Plasticity. Article ID 2173748.

Moran PM, Nawa H, O’Tuathaigh CMP, Pappaleo F, Waddington JL (2013) Dopaminergic function in relation to genes associated with risk for schizophrenia: translational models for psychotic illness. Progress in Brain Research: Dopamine. 1. 211: 79-112.

O'Callaghan MJ, Bay-Richter C, O'Tuathaigh CMP, Heery DM, Waddington JL and Moran PM (2014) Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2) deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via both D2 and non-D2 mechanisms? Journal of Psychopharmacology. 28(10), 973-977.

Chan CM, Fulton J, Montiel-Duarte C, Collins HM, Bharti N, Wadein F, Moran PM, Mongan NP and Heery DM (2013) A Signature Motif Mediating Selective Interactions of BCL11A with the NR2E/F Subfamily of Orphan Nuclear Receptors. Nucleic Acids Research 41(21):9663-79.

McIntosh AL, Ballard TM, Steward LJ, Moran PM and Fone KCF (2013). The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology. 228(1) 31-42.

O'Tuathaigh CMP, Moran PM and Waddington JL (2013) Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological ‘minefield Cell and Tissue Research.

Bay-Richter C, O'Callaghan MJ, Mathur N, O'Tuathaigh CMP, Heery DM, Fone KCF, Waddington JL and Moran PM (2013) D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors Neuropsychopharmacology. 38(8), 1512-1520.

Moran PM, Rouse JL, Cross B, Corcoran R, Schurmann M (2012) Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia. PLoS One, 7(8): e 43905.

O'Tuathaigh CM, Desbonnet L, Moran PM, Waddington JL (2012) Susceptibility genes for schizophrenia: mutant models, endophenotypes and Psychobiology. Curr Topics Behav Neurosci, 12:209-250.

O'Tuathaigh CM, Desbonnet L, Kirby, BP, Moran PM, Waddington JL (2011) Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges. Curr Top Behav Neurosci. 7: 87-119.

Le Cozannet R, Fone KC, Moran PM. (2010) Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. The International Journal of Neuropsychopharmacology. 13(8):1011-20.

O'Tuathaigh CM, Kirby BP, Moran PM, Waddington JL. (2010) Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia. Schizophrenia Bulletin, 36(2) :271-88.

Bay-Richter C, O’Tuathaigh CMP, O’Sullivan G, Heery DM, Waddington JL, Moran PM (2009) Enhanced Latent Inhibition in Dopamine Receptor Deficient Mice is Sex-Specific for the D1 but not D2 receptor subtype: Implications for Antipsychotic Drug Action. The Int. Journal of Neuropsychopharmacology 12: 403-414.

Moran PM, Owen L, Crookes AE, Al-Uzri MM, Reveley MA (2008) Abnormal prediction error is associated with negative and depressive symptoms in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32: 116-23.      

Horsley, RR, Moran, PM, Cassaday HJ (2008). Systemic amphetamine and electrolytic lesions of the nucleus accumbens (shell versus core) have dissociable effects on appetitive overshadowing. Journal of Psychopharmacology, 22: 172-81.          

Saadat KS, Elliot JM, Green AR, Moran PM (2006) High Dose MDMA does not result in long term changes in impulsivity in the rat. Psychopharmacology 188: 75-83.

Al-Uzri MM, Reveley MA, Owen L, Bruce J, Frost S, Mackintosh D, Moran PM, (2006) The prevalence of memory impairment in schizophrenia: a case controlled study. British Journal of Psychiatry 189: 132-136. 

Migo EM, Corbett K, Graham J, Smith S, Tate S, Moran PM, Cassaday HJ (2006) A novel test of conditioned inhibition correlates with personality measures of schizotypy and reward sensitivity. Behavioural Brain Research, 168 (2) 299-306. 

Annett M & Moran P (2006) Schizotypy is increased in mixed-handers especially right handed writers who use the left hand for primary actions. Schizophrenia Research, 81 (2-3), 239-246.

Young AMJ, Moran PM, Joseph MH (2005) The role of dopamine in conditioning and latent inhibition; what, where, when and how? Neuroscience and Biobehavioral Reviews, 29: 963-976.

O’Tuathaigh, CMP. & Moran, PM. (2004) The Effects of sulpiride on amphetamine-induced disruption of overshadowing in the rat. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 28, 1249-1253.

O’Tuathaigh CMP, Salum C, Pickering A, Joseph M, Young A, Moran PM (2003) Amphetamine disruption of Kamin blocking in the rat. Behavioural Pharmacology (14):315-323.      

McDonald LM, Moran PM, Vythelingum MH, Joseph MH, Stephenson JD, Gray JA (2003) Enhancement of latent inhibition by two 5-HT2a receptor antagonists only when given at two stages of the paradigm. Psychopharmacology 169, (3-4): 321 – 331. 

Crookes A. & Moran PM (2003) An investigation into age and gender differences in human Kamin blocking using a computerized task. Developmental Neuropsychology 24(1), 39-55.

Moran, PM, Al-Uzri M, Watson J, Reveley MA, (2003) Reduced Kamin blocking in non-paranoid schizophrenia: associations with schizotypy. Journal of Psychiatric Research 37, 155-163.

McDonald LM, Moran PM, Vythelingum MH, Joseph MH, Stephenson JD, Gray JA (2002) Latent inhibition is attenuated by noise and partially restored by a 5-HT2A receptor antagonist. Behavioural Pharmacology 13, 8 663-667.         

O’Tuathaigh CMP., Moran PM (2002) Evidence for dopamine D1 receptor involvement in the stimulus selection task overshadowing in the rat. Psychopharmacology 162: 225-231.

Mechan AO, Moran PM, Elliot JM, Young A, Joseph MH, Green AR (2002) A comparison between Dark agouti and Sprague-Dawley rats in their behaviour on the elevated plus maze, open field apparatus and activity meters and their response to diazepam. Psychopharmacology, 159:188-195.

Mechan AO, Moran PM, Elliott M, Young AMJ., Joseph MH, Green AR (2002) A study of the long term effect of neurotoxic degeneration induced by 3,4-methylenedioxymethamphetamine (MDMA) administration on the behaviour of rats in the plus maze and open field. Psychopharmacology 159: 167-175.

Joseph MH, Peters S, Moran PM, Gray JA (2000) Amphetamine disruption of latent inhibition in the rat depends upon dopamine transmission in the nucleus accumbens. Neuroscience 101, 4, 921-930.  

Moser PC, Lister S, Hitchcock J, Moran PM (2000) The pharmacology of latent inhibition in the rat: a review of latent inhibition as an animal model of schizophrenia.Brain Research Reviews 33, 247-282.

Gray JA, Moran PM, Grigoryan G, Peters S, Young AMJ, Joseph MH (1997) Latent inhibition: the nucleus accumbens connection revisited. Behavioural Brain Research, 88: 27-35.

Moran PM, Fischer T, Hitchcock, JM, Moser PC (1996) Effects of clozapine on latent inhibition in the rat.  Behavioural Pharmacology, 7: 1-7.                                   

Moser PC, Moran PM, Frank RA, Kehne JH (1996) Reversal of amphetamine behaviours by MDL100,907, a selective 5-HT2A antagonist. Behavioural Brain Research, 73: 163-167.        

Cordell B, Higgins L,Higaki J, Zhong Z, Moran PM, Moser PC (1995) A model of B-amyloid formation and Alzheimer s Disease. Alzheimer’s Research, 1: 111-116. 

Moran PM, Higgins LS, Cordell B, Moser PC (1995) Age-dependent learning deficits in transgenic mice expressing the 751-amino acid isoform of human B-amyloid precursor protein. Proc. of the National Academy of Sciences (PNAS) 92: 5341-5345.       

Seiler N, Grauffell C, Elanda J, Van-Den-Buuse M, Sarhan S, Moran P, Gobaille S (1994) Supression of haloperidol-induced oral dyskinesias in rats by vigabatrin. Pharmacology, Biochemistry and Behaviour, 50: 282-287.          

Moran PM (1993) Differential effects of scopolamine and mecamylamine on working and reference memory tasks in the rat. Pharmacology, Biochemistry and Behaviour, 45: 1-7.

Moran PM, LeMaitre MH, Philouze V, Reymann JM, Allain H, Van den Driessche J, Leonard BE (1992) Reversal of learning and memory impairments following lesion of the nucleus basalis magnocellularis (NBM) by concurrent noradrenergic depletion using DSP4 in the rat. Brain Research, 595: 327-333.

Moran PM, Kane JM, Moser PC (1992) Enhancement of working memory performance in the rat by MDL 26,479 a novel compound with activity at the GABAA receptor complex. Brain Research, 569 :156-158.

Moran PM & Moser PC (1992) MDL 73,147EF a 5-HT3 antagonist facilitates latent inhibition in the rat. Pharmacology, Biochemistry and Behaviour, 42, 519-522.      

Moran PM (1992) Scopolamine deficits in negative patterning discrimination Evidence for the role of the cholinergic system retention but not acquisition of non-spatial discrimination learning. Behavioural Brain Research, 48, 187-197.                                    

Moran P & Leonard BE (1989) Noradrenaline and animal cognitive processes: Implications for dementia. Irish journal of Psychological Medicine, 6: 106-108.

Allain H, Moran P, Bentue-ferrer D, Martinet JP, Lieury A (1989) The pharmacology of the memory process. Archives of Geriatrics and Gerontology, vol. 1, 109-120.

Allain H, Bentue D, Milon D, Moran P, Defawe G (1989) Pregnancy and parkinsonism: A case report without problem. Clinical Neuropharmacology, 12, 217-219.

Books chapters and Other publications

Published abstracts